Genetic basis of susceptibility to drug-induced liver injury: What have we learned and where do we go from here?

Pharmacogenomics

Volumn 13, Issue 7, 2012, Pages 735-738

  Urban, Thomas J ^a   Goldstein, David B ^a   Watkins, Paul B ^b,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Hamner University of North Carolina Institute for Drug Safety Sciences   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Genome wide association studies; GWAS; Hepatotoxicity; Pharmacogeneticspharmacogenomics; Whole genome sequencing

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; DNA; FLUCLOXACILLIN; ISONIAZID; LAPATINIB; LUMIRACOXIB; XIMELAGATRAN;

ACUTE LIVER FAILURE; DNA SEQUENCE; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MORBIDITY; PHENOTYPE; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TOXIC HEPATITIS;

ARYLAMINE N-ACETYLTRANSFERASE; DRUG-INDUCED LIVER INJURY; FLOXACILLIN; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; ISONIAZID; POLYMORPHISM, SINGLE NUCLEOTIDE; STAT4 TRANSCRIPTION FACTOR;

EID: 84861181310     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.45     Document Type: Review

References (15)

1. Ostapowicz G, Fontana RJ, Schiodt FV et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137(12), 947-954 (2002). (Pubitemid 35440240)
2. Sgro C, Clinard F, Ouazir K et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36(2), 451-455 (2002). (Pubitemid 34810366)
3. Watkins PB. Drug safety sciences and the bottleneck in drug development. Clin. Pharmacol. Ther. 89(6), 788-790 (2011).
4. Daly AK. Drug-induced liver injury: past, present and future. Pharmacogenomics 11(5), 607-611 (2010).
5. Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Drug Metab. Rev. 44(1), 116-126 (2012).
6. Holmes MV, Shah T, Vickery C, Smeeth L, Hingorani AD, Casas JP. Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PLoS ONE 4(12), E7960 (2009).
7. Fontana RJ, Watkins PB, Bonkovsky HL et al. Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 32(1), 55-68 (2009).
8. Andrade RJ, Lucena MI, Fernandez MC et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129(2), 512-521 (2005). (Pubitemid 41096639)
9. Molokhia M, Mckeigue P. EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions. Pharmacogenomics 7(4), 633-638 (2006).
10. Daly AK, Donaldson PT, Bhatnagar P et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41(7), 816-819 (2009).
11. Kindmark A, Jawaid A, Harbron CG et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 8(3), 186-195 (2008). (Pubitemid 351712643)
12. Spraggs CF, Budde LR, Briley LP et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J. Clin. Oncol. 29(6), 667-673 (2011).
13. Singer JB, Lewitzky S, Leroy E et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet. 42(8), 711-714 (2010).
14. Lucena MI, Molokhia M, Shen Y et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 141(1), 338-347 (2011).
15. Rashid ST, Corbineau S, Hannan N et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J. Clin. Invest. 120(9), 3127-3136 (2010).